Although technologies and markets have changed dramatically during the last 25 years, the investment principles upon which Sevin Rosen Funds was founded in 1981 have not. The Sevin Rosen team, all seasoned high-tech executives, always takes a very active and team-oriented approach to helping entrepreneurs throughout every stage of the company-building process.  Sevin Rosen Funds examine technology trends, identifying those technologies they believe will transform entire industries. Their emphasis is on what will happen next, what will succeed, and then, what will endure.  Sevin Rosen Funds mean what they say. In the venture capital world -- a world based almost entirely on personal relationships -- their word and their good name are their most valuable assets. And in all their relationships, they 've consistently placed a premium on honesty and fairness.

Sevin Rosen Funds

The Aurora Funds is a family of venture capital funds committed to providing resources to help early stage healthcare and information technology companies reach their full potential.

The Aurora Funds

The Trelys Funds is a North Carolina-based venture capital firm focused on early- to mid-stage investments in a variety of industries.

The Trelys Funds

With some 25 tiny technology companies in our portfolio, Harris & Harris Group, Inc.Â®, is one of the most active nanotechnology investors in the world. They have funded companies developing nanoscale-enabled solutions in solid state lighting, emerging memory devices, printable electronics, material science discovery and mass-manufacturing, organic-inorganic hybrids, next-generation semiconductor devices and equipment, thermoelectric, photovoltaic and battery technologies, as well as in various life-science applications of nano-structured materials.  They participate in venture capital syndicates in most of their investments, alongside top-tier venture capital firms as well as strategic (corporate) investors. Increasingly, Harris & Harris Group is a lead investor. They believe in the classical early stage venture capital model and disciplines and that most technology-based start-ups can use all the help they can get from the diversified experiences, RolodexesÂ®, complimentary business networks, technical expertise, up-to-date customer connections and financial resources that a syndicate of professional venture capital investors can provide.  Harris & Harris Group will invest at any stage prior to a company's initial public offering, and they will invest anywhere in the United States. Occasionally, they have also made private investments in publicly held companies (so-called ''PIPE'' investments). They have invested outside the United States, but rarely. Their current portfolio companies are distributed all across the country, plus one in Canada.  Harris & Harris Group is looking for scientific, technological, business and execution excellence. They are attracted to markets of significant size and back passionate entrepreneurs who want to change the world with their tiny technology-enabled products.  Proprietary, well-protected and highly differentiated technology is a prerequisite. But above all, they are eager to invest in companies with market-centric strategies that seek to define and dominate large product categories.

180 Degree Capital

Alexandria Real Estate Equities is a real estate company. They offer engineering, asset management, laboratory operations, life science, construction, planning, health and environment, safety, project management, finance, collaboration, accounting, communications and public relations, events, venture investment, and sustainability.

Alexandria Real Estate Equities

Syngenta Ventures is the corporate venture capital (VC) team of Syngenta, a leading agriculture company helping to improve global food security by enabling farmers to make better use of available resources. Created in 2009, Syngenta Ventures was one of the first venture capital teams dedicated to agriculture. With an experienced team of investment professionals possessing more than 45 collective years of VC experience, Syngenta Ventures has established itself as one of the most active and knowledgeable agricultural investors. Syngenta Ventures is stage agnostic, from investing in seed rounds to larger growth equity rounds. They typically invest alongside other financial and corporate VC investors, and they avoid asking for any rights or options for Syngenta as they recognize the importance of having the interests of all shareholders aligned. They use their deep experience as investors and running commercial Ag businesses to work with their portfolio companies to help them maximize their potential value. They often take board or board observer roles, spending the time needed with the company and management to help them achieve their goals. Finally, they are connected into Syngenta, ranging from R&D to commercial teams, around the world. They can help their portfolio companies validate new products in field trials, increase market visibility, and share industry knowledge and contacts. While they encourage technical and/or commercial collaboration with Syngenta, these are negotiated by Syngenta and not connected to their investment. Linked to this, they maintain a strict firewall with Syngenta to protect any confidential information from being shared. They take this responsibility seriously and can provide references from their portfolio companies to demonstrate this.

Syngenta Ventures

Strategy consulting to innovate and accelerate organic and inorganic growth. We have a deep reputation for developing actionable insights that are typically delivered as a growth plan.

Fletcher Spaght, Inc.

Crossroads Capital is a closed-end fund regulated as a business development company under the Investment Company Act of 1940, as amended (the ''1940 Act''). Its investment objective is to maximize total return by generating current income from debt investments and, to a lesser extent, capital appreciation from equity and equity-related investments.

Crossroads Capital

Camden Partners provides growth capital to lower-middle market companies in the education, healthcare and technology-enabled business services sectors. In areas where there is little common knowledge, they make it their business to know intimately the companies and the money managers in which they invest. While many other investment management firms seek to excel as stock-pickers, they pursue opportunities where their experience and influence will make a positive difference to both their investors and the companies in which they invest.

Camden Partners

Sumitomo Corporation is a business services company that works with import, export, trilateral trade, and business investment in Japan. With its global network and based on trust from companies in various industries and from consumers, Sumitomo Corporation engages in multifaceted business activities by making the most of its Integrated Corporate Strength. These business activities include sales of a variety of products and services within Japan, import and export, trilateral trade, and domestic and international business investment. It was founded in 1919 and is based in Tokyo, Japan.

Sumitomo

Fulcrum Equity Partners is a growth equity firm investing in high-growth SaaS, tech-enabled services, healthcare services and healthcare IT companies.  Founded in 2006 and based in Atlanta, GA, Fulcrum has raised over $280 million across three funds and has invested in more than 30 companies.    Fulcrum will consider non-control and control investments, and provides capital to meet a variety of needs including internal growth initiatives, acquisitions, divestitures, shareholder liquidity, management buyouts and recapitalizations.  The partners have over 125 years of relevant experience, including operations, venture capital, mezzanine financing, accounting, law, investment banking and strategy consulting.  For more information, please visit www.fulcrumep.com.

Fulcrum Equity Partners

Aurora Venture Capital is an investment fund that was founded in 2010. The Key investment focus of the fund lies in investing in fast-growing online properties and high-tech projects globally.  Aurora Venture Capital provides its investors with an opportunity to invest in a divers field of growth with several private IT companies gain multiple returns on their investments, which rarely happens with public companies.

Aurora Venture Capital Fund

Metabolon

Metabolon is a technology company, that develops analytical methods and software for biomarker discovery using metabolomics. Metabolon's expertise in data and translational science enables customers and partners to tackle some of the most complex and urgent questions in the life sciences, thereby accelerating research and improving development outcomes. The company provides scalable and customizable multiomics solutions, including metabolomics and lipidomics, to support customer needs from discovery through clinical trials and throughout the product lifecycle. The company aims to provide biochemical data and insights that broaden and hasten the impact of life sciences research, while also integrating seamlessly with other 'omics' technologies.

Metabolon is specialized in metabolomics, offering state-of-the-art solutions that advance research across a range of applications including drug development, diagnostics, and precision medicine.

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Metabolon Expands Library to Include 70 Pesticides, Advancing Human Exposome Insights through Metabolomics

Metabolon is specialized in metabolomics, offering state-of-the-art solutions that advance research across a range of applications including drug development, diagnostics, and precision medicine.The company's flagship Global Discovery Panel is claimed to leverage the world's largest proprietary metabolomics reference library, comprising over 5,400 metabolites, enabling comprehensive profiling and identification of small molecules in biological systems. Metabolon's technology deciphers thousands of discrete chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways.Metabolon also provides targeted panels and assays covering over 1,000 metabolites and lipids across various biochemical classes, metabolic pathways, and physiological processes. These panels can be customized to suit specific applications, such as the Complex Lipids Panel, Bile Acids Targeted Panel, Short Chain Fatty Acids Targeted Panel, and Diabetes Research Markers Targeted Panel.&nbsp;The company had made two acquisitions as of July 2024: Metabolomic Discoveries GmbH in September 2017 and Lipomics in August 2012. Key customers and partnershipsIn March 2024, Metabolon entered a strategic partnership with the Cardiff University Centre for Neuropsychiatric Genetics and Genomics to explore novel pathogenic mechanisms of amyotrophic lateral sclerosis (ALS). This collaboration aimed to leverage metabolomics to deepen the understanding of ALS and potentially identify new therapeutic avenues for this devastating disease.Other notable partnerships include that with the Sheffield Institute for Translational Neuroscience (SITraN) and A Multicentre Biomarker Resource Strategy in ALS (AMBRoSIA) to drive biomarker discovery efforts in ALS and other motor neuron diseases. This partnership involves profiling plasma and cerebrospinal fluid samples from ALS patients and controls, with the goal of uncovering new insights and potential biomarkers for precision medicine approaches.

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

PROMINENT_CATEGORY

<div>
 
 Metabolon has teamed up with the Scottish Early Rheumatoid Arthritis (SERA) Study to discover potential biomarkers for rheumatoid arthritis. The goal of the collaboration is to find circulating small molecules that may indicate a patient's risk of developing the disease, monitor the progression of the disease, and track how a patient is responding to treatment. The study will leverage Metabolon's comprehensive library of small molecules and SERA's well-documented patient group to integrate metabolomic data with clinical and genomic information.
 This initiative has been designed to enhance the current understanding of the molecular mechanisms at the core of rheumatoid arthritis. The insights obtained from this process might lead to the development of more effective diagnosis and treatment strategies for this disease.
 
</div>

Metabolon

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless